The relationship between antibiotic use in humans and poultry and antibiotic resistance prevalence in humans: an ecological

regression study of *Campylobacter* in the UK

Short title: cross-species ABU and ABR rates in UK Campylobacter infections

Eve Emes*, Javier Guitian, Gwenan M Knight**, Nichola Naylor**,

*Corresponding author **Joint last authors

Abstract

Antibiotic resistance (ABR), the capacity of bacterial pathogens to survive in the presence of antibiotics, is an increasingly pressing issue for human health worldwide. The use of antibiotics (ABU) in humans and livestock animals, is considered the main driver of the global increase in ABR prevalence, but the shape and size of this relationship at the population level is still uncertain.

In the UK, the bacterial pathogen *Campylobacter* is a major cause of foodborne infection, with most infections attributed to poultry. It is a strong case study to investigate the ecological relationship between antibiotic use and resistance across humans and animals. Despite significant reductions in ABU in humans and poultry over the last decade, the rate of ABR in *Campylobacter* infections in the UK has remained relatively high.

We compiled data on *Campylobacter* infections and the use of antibiotics in primary care, secondary care, and poultry health in the UK from 2011 to 2022 (human data were from England only). Using pooled ordinary least squares regression, we investigated the relationship between the rate of ABR in *Campylobacter* infections and the quantity of ABU in each of these three sectors. We also explored the shape and size of this relationship using different specifications.

Our results suggest that the rate of antibiotic resistance in human *Campylobacter* infections in the UK was positively linked with use of antibiotics in humans, with some evidence that it was also linked to antibiotic use in poultry. However, antibiotic use explained only a relatively small portion of the changes in resistance. For human health, we found evidence that the relationship between (antibiotic) use and resistance weakens over time as resistance builds up in the human population, supporting the idea of a resistance threshold beyond which resistant strains become endemic and reductions in use become less effective.

Our results suggest that reducing use alone may not be sufficient to bring the level of ABR in *Campylobacter* down to desirable levels. While antibiotic stewardship remains essential, future policy and research on *Campylobacter* should dedicate focus to transmission factors, safeguarding new antibiotics in people, and alternative and complementary therapies for poultry infection such as vaccination and bacteriophages.

Acknowledgements

The authors wish to extend their thanks to collaborators at the British Poultry Council (BPC), the UK Health Security Agency (UKHSA), the UK Animal and Plant Health Agency (APHA), the London School of Hygiene and Tropical Medicine (LSHTM), and the Royal Veterinary College (RVC). Their inputs have been essential in formulating the scope, design and content of the investigation, and have allowed this project to be truly interdisciplinary.

Introduction

Antibacterial resistance (ABR), the capacity of bacterial pathogens to survive in the presence of antibiotics, poses a significant and growing threat to human health globally(1,2). The growth in ABR has been driven by the antibiotic use (ABU) by humans, in both animal and human health. As such, global health policy has placed emphasis on reducing ABU in order to reduce the prevalence of ABR.

However, it is unclear how effectively, and under what conditions, a reduction in ABU in humans and livestock can bring down the currently high prevalence of ABR. If ABU reductions alone are unlikely to bring down the prevalence of existing resistant pathogen strains to desirable levels, then this can help to guide resources towards policies focusing on transmission and alternative treatments. We must therefore understand the way that ABU and ABR relate to each other at the population level.

Accurately quantifying the ecological relationship between ABR and ABU is also necessary in order to design and prioritise stewardship policies at the national level(3). Especially when policies incur an opportunity cost (e.g. limiting antibiotic use in people or livestock), it is important to understand the number of resistant infections that are likely to be averted from a given change in ABU in order to predict their health-economic impact.

For this reason, we set out to investigate the ecological relationship between antibiotic use (in humans and livestock) and ABR in humans, using *Campylobacter* in the UK as a case study.

We chose *Campylobacter* as a candidate for analysis for a number of reasons. For one, the foodborne gastrointestinal complaint 'campylobacteriosis' is medically important, being the main cause of zoonotic infections in the EU in 2020(4) and having grown in prevalence in the UK in recent decades(5). Campylobacterioses are usually treated with macrolides and fluoroquinolones, both clinically important classes of antibiotics(6). *Campylobacter* has also received a lot of policy attention in the UK, and concerns about transmission of resistant *Campylobacter* from poultry have spurred a sharp decrease in antibiotic use in UK poultry production(7,8). Due to data availability, human infection and ABU data were from England only while poultry ABU data covered the whole of the UK.

This case study also lends itself well to statistical analysis. As fresh poultry is the source of most *Campylobacter* infections in the UK(5,9), any link with animal ABU will be easier to identify. This is especially true given the sharp decrease in poultry ABU since 2013. While the rise in resistance of *Campylobacter Spp* to key antibiotic classes has been attributed to ABU in animal production, the link is highly controversial(10) and it is important to test this

claim. Campylobacter infections also tend to be sporadic rather than occurring in discrete outbreaks(5), meaning that outbreak transmission is less likely to obscure analysis.

If ABU in poultry and humans is key to the development of resistance in human Campylobacter infections, then we would expect to see a positive relationship between ABU and ABR in humans. Given that the recent fall in ABU, especially in poultry, has not (yet) been mirrored by a commensurate fall in human ABR, we hypothesised that there may be a threshold level of resistance beyond which resistant strains become endemic and the relationship between use and resistance breaks down.

Emes et al.(3), identifies regression analysis as an underexploited resource for understanding and characterising the ecological relationship between ABR and ABU. To our knowledge, the is the first study to do so for Campylobacter infections in the UK. Throughout the study, we maintained a One Health approach and collaborated with stakeholders from a range of sectors, reflecting the interdisciplinary nature of our study questions.

We therefore aim to explore the relationship between ABU and ABR in Campylobacter infections in the UK using regression analyses, and also to test the robustness of these models using a range of cutoffs, interactions, nonlinearities, lags, and covariates.

Stakeholder engagement manuscript In designing the investigation and interpreting results, we held multiple rounds of stakeholder engagement with members of the poultry industry, the British Poultry Council (BPC), the UK Health Security Agency (UKHSA), the UK Animal and Plant Health Agency (APHA), the UK Veterinary Medicines Directorate (VMD), the London School of Hygiene and Tropical Medicine (LSHTM), and the Royal Veterinary College (RVC). We used these meetings to codesign the project and to create this paper.

The original plan for this paper was created as part of the SEFASI consortium(11) based at the LSHTM. We created an initial pre-analysis plan, and then recruited twenty collaborators from the above organisations through our own contacts and through snowball sampling. We sent the pre-analysis plan to them, and on 16 November 2022 we held a workshop in which we refined the plan based on their inputs. Data on antibiotic use in poultry were obtained from the BPC, and data on antibiotic use and infections in humans were obtained from the UKHSA. After obtaining the data, we ran results and created a draft of this manuscript, and elicited feedback and authorial input from stakeholders.

Statistical methods

All statistical analyses, including cleaning, were performed in R version 4.1.2(12). Statistical analyses were reported in accordance with the Basic Statistical Reporting for Articles Published in Biomedical Journals (SAMPL) guidelines(13).

Creating the dataset

Data on human ABU and infections came from the UKHSA and covered England only. Infection data covered laboratory-diagnosed Campylobacter spp. infections from blood and faecal specimens, with susceptibility tests for key antibiotic classes conducted. Data on poultry ABU (UK-wide) came from the BPC. Human data were accessed on 12 May 2023. The authors did not have access to information which could identify individual participants during or after data collection.

We combined our data into a unified dataset, harmonising antibiotic classes across datasets. This was done because antibiotic groups were recorded differently across the datasets used (see Appendix I for a chart of how antibiotics were grouped into harmonised classes). The final dataset included guarterly data on the use of antibiotics in primary care¹ from 2013 to 2022 across 17 antibiotic classes, quarterly ABU in secondary care from 2017 to 2022 across 18 antibiotic classes, annual use in poultry from 2011 - 2021 across eight antibiotic classes, and the guarterly rate of resistance (portion of tested isolates resistant) in human Campylobacter infections from 2014 to 2019 across seven antibiotic classes.

Because of a lack of overlap in antibiotic classes and years covered in the original datasets, and because antibiotic use in poultry was only available annually, we had only fifteen complete cases. See Appendices I and II for more information on data completeness.

Upon creating the final dataset, we explored the data and produced summary statistics and see mar figures.

Regression analysis

We had initially planned to use fixed and random effects models to investigate the relationship between antibiotic use and resistance, and to include all of our key covariates in every specification. However, a lack of statistical power due to data availability and overlap meant that we were obliged to use pooled ordinary least squares (OLS) instead, and to rely more heavily on univariate specifications. We used a log-log specification as in Rahman and Hollis(14), regressing log resistance against log use. For robustness, we also regressed resistance against use linearly, and redid our main specifications using the (log) number of resistant infections reported as the outcome. Throughout this paper, log refers to the natural logarithm.

Our basic model was as follows:

(1) $log(Resistance_{it}) = \beta_0 + \beta_1 * log(Use_{it}) + u_{it}$

Where Use it refers to use of antibiotic i in period t, Resistance it is the portion of tested Campylobacter isolates which were resistant to antibiotic i in period t, and $u_{i,t}$ is the error term.

¹ We had originally intended to group human antibiotic use into a single category, but as data on ABU in primary and secondary care covered different time periods we elected to include them separately

We first ran our basic model univariately against use in each of the three sectors (primary care, secondary care, poultry), as well as against use in both primary care and poultry, and against use in all three sectors.

After this, we explored models with a lagged independent variable, both on its own and in combination with same-period covariates, to test if ABU had a delayed effect on resistance. We also looked at lagged dependent variables. Lags were one period (one quarter for human ABU and one year for animal ABU). Lags were investigated because, in humans, it may take time for resistant infections to develop and be tested, and in poultry there is a delay between antibiotics being used and the animals being slaughtered and consumed. It may also take time for resistance to spread between people and for prevalence to grow. The specifications used were:

(2)
$$log(Resistance_{i,t}) = \beta_0 + \beta_1 * log(Use_{i,t-1}) + u_{i,t}$$

(3) $log(Resistance_{i,t}) = \beta_0 + \beta_1 * log(Use_{i,t}) + \beta_2 * log(Use_{i,t-1}) + u_{i,t}$

Following this, we investigated nonlinearities and threshold effects. We first added a quadratic term to see if this would be a more appropriate functional form, i.e.

(4)
$$log(Resistance_{i,t}) = \beta_0 + \beta_1 * log(Use_{i,t}) + \beta_2 * (log(Use_{i,t}))^2 + u_{i,t})$$

We then investigated the idea of a resistance 'threshold', i.e. that idea that, beyond a certain level of resistance, resistant strains become endemic and therefore the relationship between use and resistance breaks down. This is especially worth investigating because, for several antibiotic classes such as fluoroquinolones, we have seen a significant fall in total use in the UK in recent years without an accompanying fall in resistance in *Campylobacter* infections.

In order to do this, we first investigated whether or not the relationship between use and resistance differed at low-medium levels of resistance relative to at high levels, truncating specification (1) and seeing if it had greater explanatory power and significance below a certain level of resistance, i.e.

(5)
$$log(Resistance_{i,t})[Resistance_{i,t} \le X] = \beta_0 + \beta_1 * log(Use_{i,t}) + u_{i,t}$$

Where *X* is a proposed threshold level of resistance.

After this, we looked at the interaction between human and poultry antibiotic use, i.e.

(6) Resistance
$$_{i,t} = \beta_0 + \beta_1 * log(Use \stackrel{human}{i,t}) + \beta_2 * log(Use \stackrel{poultry}{i,t}) + \beta_3 * log(Use \stackrel{human}{i,t}) * log(Use \stackrel{poultry}{i,t}) + u_{i,t}$$

Understanding the interaction between use in humans and use in poultry is important for guiding national antibiotic use policy. For certain antibiotic classes, use in poultry has fallen significantly while use in humans has fallen less or remained constant, with the rate of resistance in *Campylobacter* infections also not falling. It is possible that continued high use

in humans has limited the effectiveness of ABU reduction in poultry, which we wanted to investigate here.

We then looked at the role of the amount of time since a given antibiotic was introduced. Some previous research on this ecological relationship, e.g. Adda, 2020(15), has suggested that the link between ABU and ABR is stronger for more recently introduced antibiotics. We did this by regressing resistance against use, against the time since the relevant class was introduced clinically, and against an interaction term, i.e.

(7) Resistance $_{i,t} = \beta_0 + \beta_1 * log(Use_{i,t}) + \beta_2 * log(Time.since.introduction_i) + \beta_3 * log(Use_{i,t}) * log(Time.since.introduction_i) + u_{i,t}$,

Where *Time.since.introduction* $_i$ is the number of years since the clinical introduction of a given antibiotic class as of 2019, the last year for which resistance data were available.

Finally, we looked at the role of poultry production. Sourcing data on the total poultry produced in each quarter from the UK Department for Agriculture and Rural Affairs (DEFRA)(16), we added this as a covariate and interacted it with ABU. Since most *Campylobacter* infections in the UK come from poultry(5,9), it is important to see if this production affects the relationship between ABU and ABR, i.e.

201


(8) Resistance
$$\beta_0 + \beta_1 * log(Use_{i,t}) + \beta_2 * log(Poultry.production_t) + \beta_3 * log(Use_{i,t}) * log(Poultry.production_t) + u_{i,t}$$

Results

Summary statistics

In total, we had 191 observations of human resistance prevalence, 99 observations of poultry ABU, 800 observations of ABU in primary care, and 528 observations of ABU in secondary care, with 15 complete cases.


We first plotted the total use of antibiotics in the UK over time, across the three sectors investigated (primary care, secondary care, and poultry health) (figure 1, below)



We can observe that antibiotic use in poultry grew rapidly from 2011 until 2013, and then sharply fell and has remained low since 2016 (Figure 1). Use in primary healthcare gradually fell from 2013 until the outbreak of the COVID-19 pandemic in the UK in early 2020 (vertical line), and since then has returned roughly to the previous trend. Use in secondary care remained fairly constant from 2017 to 2020 and again fell sharply at the onset of the COVID-19 pandemic, and has since returned roughly to pre-pandemic levels.

Figure 2 shows ABU (in all three sectors) and resistance over time for the five antibiotic classes for which we had both resistance data and use data across all sectors. It highlights that these five key classes seemed to follow a similar trend: use in humans either remained steady or fell (with the fall being more pronounced in primary care), use in poultry grew up to 2013 and then fell rapidly and remained low, and resistance either remained steady or rose somewhat.

Figure 2: Antibiotic use across three sectors (points) and resistance prevalence in tested *Campylobacter* isolates (purple line) over time for selected antibiotic classes



Regression analysis

We first ran specification (1), investigating the relationship between use and resistance in the basic specification (Figure 3)

Figure 3 - relationship	between antibiotic	use and resistance	(log prevalence - log	g use)
-------------------------	--------------------	--------------------	-----------------------	--------

		Log Rate of Resistance	e of Campylobacter	Samples Tested	
	(1)	(2)	(3)	(4)	(5)
Antibiotic Use in Primary Care (Log DDDs)	1.165***			1.318***	0.187
	(0.142)			(0.436)	(0.264)
Antibiotic Use in Secondary Care (Log DDDs)		3.265***			0.344
		(0.784)			(0.750)
Antibiotic Use in Poultry (Log Tonnes)			0.139	-0.810*	-0.241
			(0.280)	(0.399)	(0.181)
Constant	-20.354***	-51.302***	-2.318***	-22.060***	-9.484
	(1.924)	(11.025)	(0.759)	(6.571)	(9.139)
Ν	167	83	30	30	15
R ²	0.291	0.177	0.009	0.259	0.147
Adjusted R ²	0.287	0.166	-0.027	0.204	-0.086
Residual Std. Error	6.998 (df = 165)	7.909 (df = 81)	4.148 (df = 28)	3.652 (df = 27)	1.062 (df = 11)
F Statistic	57.838 ^{***} (df = 1; 165) 17.363 ^{***} (df = 1; 81) 0.246 (df = 1; 28)	4.718^{**} (df = 2; 27)	0.630 (df = 3; 11)
Notes:		201	10	***Significant at	the 1 percent level.
		at V		**Significant at	the 5 percent level.
	SCRI	<i>P</i> .			ne 10 percent level.
	S				

Figure 4 relationship between antibiotic use and resistance (linear)

		Rate of Resistance	of Campylobacter S	amples Tested	
500	(1)	(2)	(3)	(4)	(5)
Antibiotic Use in Primary Care (Millions of DDDs)	0.006***			0.002	-0.001
	(0.002)			(0.001)	(0.003)
Antibiotic Use in Secondary Care (Millions DDDs)		0.025**			0.005
		(0.012)			(0.011)
Antibiotic Use in Poultry (Tonnes)			0.012**	0.004	0.022
			(0.005)	(0.007)	(0.030)
Constant	0.273***	0.254***	0.254***	0.207***	0.248**
	(0.029)	(0.039)	(0.049)	(0.059)	(0.089)
N	167	83	30	30	15
R ²	0.043	0.051	0.162	0.218	0.296
Adjusted R ²	0.038	0.039	0.132	0.160	0.103
Residual Std. Error	0.282 (df = 165)	0.265 (df = 81)	0.210 (df = 28)	0.206 (df = 27)	0.195 (df = 11)
F Statistic	7.468^{***} (df = 1; 165)	4.370^{**} (df = 1; 81)	5.407^{**} (df = 1; 28)	3.772^{**} (df = 2; 27)	1.538 (df = 3; 11

Notes:

***Significant at the 1 percent level.

**Significant at the 5 percent level.

*Significant at the 10 percent level.

Figure 5 - relationship between antibiotic use and resistance (log number of resistant infections - log use)

	Log Number of Resistant Infections				
	(1)	(2)	(3)	(4)	
Antibiotic Use in Primary Care (Log DDDs)	1.363***			-3.099*	
	(0.120)			(1.473)	
Antibiotic Use in Secondary Care (Log DDDs))	0.613***		11.757***	
		(0.112)		(3.421)	
Antibiotic Use in Poultry (Log Tonnes)			1.154***	-0.174	
			(0.345)	(0.483)	
Constant	-30.439***	-22.803***	-6.258***	-123.633***	
	(1.433)	(1.403)	(1.840)	(39.016)	
N	480	264	54	21	
R ²	0.211	0.102	0.177	0.533	
Adjusted R ²	0.210	0.099	0.162	0.451	
Residual Std. Error	10.978 (df = 478)	11.300 (df = 262)	12.722 (df = 52)	9.557 (df = 17)	
F Statistic	128.056 ^{***} (df = 1; 478) 29.819 ^{***} (df = 1; 262)	11.211**** (df = 1; 52)	6.470^{***} (df = 3; 17)	

Notes:

Significant at the 1 percent level.

Significant at the 5 percent level. Significant at the 10 percent level.

In the log-log univariate specification (Figure 3), we found that the elasticity of resistance with respect to ABU in primary care was 1.165 (i.e. a 1% increase in use in primary care is associated with a 1.165% increase in resistance, and vice-versa). The figure for secondary care was much more elastic at 3.265. Use in both primary and secondary care was positively associated with the rate of resistance in the linear specification (although the level of explanatory power was lower) (Figure 4). When using the number of resistant infections as an outcome (Figure 5), the elasticity of resistance with respect to primary care use was similar (1.363), and the elasticity of resistance with respect to secondary care use was lower but still positive, although it was much higher when controlling for use in all three sectors.

In some multivariate specifications (Figures 3, 5), resistance had a negative relationship with use, although these coefficients had a low level of statistical significance. Use in poultry was positively associated with resistance in the second and third specifications only (Figures 4 & 5).

Overall, these specifications had a low level of explanatory power, with an adjusted R² ranging from 0.03 to 0.3. The exception was when using the number of resistant infections (instead of portion resistant) as an outcome and controlling for use in all three sectors. However, this result may be endogenous given that high resistance leads to greater hospitalisation and thus greater antibiotic use in secondary care. While Campylobacter infections very rarely lead to hospitalisation, the level of ABR in Campylobacter is likely related to the level of ABR in other pathogens, meaning that both the number hospitalisations (and therefore use of antibiotics in secondary care) and the level of ABR in Campylobacter may be co-caused.

We then regressed ABR against lagged antibiotic use (in each sector), as well as against lagged resistance (Figures 6 and 7). Lags were one quarter for human use, and one year for poultry use (longer lags were explored but were not significant).

Figure 6 - relationship	between ABR and lagged antibiotic use
-------------------------	---------------------------------------

	ate of Resistance of Ca		
(1)	(2)	(3)	(4)
1.133***			
(0.142)			
	3.085***		
	(0.824)		
		0.597	
		(0.503)	
			0.480***
			(0.066)
-19 880***	-48 712***	-4 520***	-3.162***
			(0.696)
			182
			0.226
			0.221
			7.806 (df = 180)
146^{***} ($4f = 1.16$	6) 14 002 ^{***} (df = 1 \cdot 7	(5) + 410 (dt = 1.28)	
046*** (df = 1; 16	5) 14.002*** (df = 1; 7	***Significan Significan	t at the 1 percent le t at the 5 percent le
046*** (df = 1; 16	cor d	***Significan Significan Significant	t at the 1 percent le t at the 5 percent le at the 10 percent le
	6) 14.002*** (df = 1; 7 Log Number of Res (2)	***Significan Significan Significant	t at the 1 percent le t at the 5 percent le
	Log Number of Res	*** Significan Significant Significant	t at the 1 percent let t at the 5 percent le at the 10 percent le
	Log Number of Res	*** Significan Significant Significant	t at the 1 percent let t at the 5 percent le at the 10 percent le
	Log Number of Res	*** Significan Significant Significant	t at the 1 percent let t at the 5 percent le at the 10 percent le
	Log Number of Res (2)	*** Significan Significant Significant	t at the 1 percent let t at the 5 percent le at the 10 percent le
	Log Number of Res (2) 0.582***	*** Significan Significant Significant	t at the 1 percent let t at the 5 percent le at the 10 percent le
7	Log Number of Res (2) 0.582***	***Significan Significant Significant sistant Infections (3)	t at the 1 percent let t at the 5 percent le at the 10 percent le
	Log Number of Res (2) 0.582***	*** Significan Significant Significant sistant Infections (3) 1.166***	t at the 1 percent le t at the 5 percent le at the 10 percent le (4)
	Log Number of Res (2) 0.582***	*** Significan Significant Significant sistant Infections (3) 1.166***	t at the 1 percent le t at the 5 percent le at the 10 percent le
(1) 1:337**** (0.120)	Log Number of Res (2) 0.582*** (0.114)	*** Significan Significant Significant sistant Infections (3) 1.166***	t at the 1 percent le t at the 5 percent le at the 10 percent le (4) 0.632***
	Log Number of Res (2) 0.582***	*** Significan Significant Significant (3) 1.166*** (0.355)	t at the 1 percent le t at the 5 percent le at the 10 percent le (4) 0.632*** (0.084)
(1) 1:337*** (0.120) -30.158***	Log Number of Res (2) 0.582*** (0.114) -22.454***	*** Significan Significant Significant Sistant Infections (3) 1.166**** (0.355) -7.387***	t at the 1 percent le t at the 5 percent le at the 10 percent le (4) 0.632*** (0.084) 1.608*
(1) 1:337*** (0.120) -30.158*** (1.433)	Log Number of Res (2) 0.582*** (0.114) -22.454*** (1.423)	**** Significan Significant Significant Sistant Infections (3) 1.166**** (0.355) -7.387*** (1.896)	t at the 1 percent le t at the 5 percent le at the 10 percent le (4) 0.632*** (0.084) 1.608* (0.880)
(1) 1:337*** (0.120) -30.158**** (1.433) 483	Log Number of Res (2) 0.582*** (0.114) -22.454*** (1.423) 245	**** Significan Significant Significant Sistant Infections (3) 1.166**** (0.355) -7.387*** (1.896) 54	t at the 1 percent le t at the 5 percent le at the 10 percent le (4) 0.632*** (0.084) 1.608* (0.880) 184
(1) 1:337 (0,120) -30.158*** (1.433) 483 0.204	Log Number of Res (2) 0.582*** (0.114) -22.454*** (1.423) 245 0.098	*** Significan Significant Significant Sistant Infections (3) 1.166**** (0.355) -7.387*** (1.896) 54 0.172	t at the 1 percent le t at the 5 percent le at the 10 percent le (4) 0.632*** (0.084) 1.608* (0.880) 184 0.237
	1.133*** (0.142) -19.880*** (1.922) 168 0.278 0.274 7.044 (df = 166)	(0.142) 3.085*** (0.824) -19.880*** (1.922) 168 77 0.278 0.157 0.274 0.146	(0.142) 3.085^{***} (0.824) 0.597 (0.503) (1.922) (11.578) (1.365) 168 77 30 0.278 0.157 0.048 0.274 0.146 0.014

**Significant at the 5 percent level.

*Significant at the 10 percent level.

Across the three sectors, lagged use had a similar level of significance and explanatory power as same-period use, with coefficients of a similar size. However, when we included both lagged and same-period use together the coefficients were not significant. Given the strong link between resistance across periods, we don't find convincing evidence that lagged use has an independent effect on resistance.

When then ran our specifications including a quadratic term (below).

	Log Rate of Resistance of Campylobacter Samples Tested				
	(1)	(2)	(3)		
Antibiotic Use in Primary Care (Log DDDs)	10.231***				
	(1.348)				
Squared Term	-0.366***				
	(0.054)				
Antibiotic Use in Secondary Care (Log DDDs)		104.463***			
		(18.839)			
Squared Term		-3.579***			
-		(0.666)			
Antibiotic Use in Poultry (Log Tonnes)			0.528		
			(0.362)		
Squared Term		110	0.142		
		i atails	(0.087)		
Constant	-70.918***	762.139***	-3.427***		
	(7.679)	(132.586)	(1.003)		
N	167	83	30		
R ²	C(12 0.446	0.395	0.098		
Adjusted R ²	0.439	0.380	0.031		
Residual Std. Error	6.209 (df = 164)	6.821 (df = 80)	4.030 (df = 27)		
R ² Adjusted R ² Residual Std. Error F Statistic	65.893 ^{***} (df = 2; 164)	26.117^{***} (df = 2; 80)	1.460 (df = 2; 27)		
Notes:		***Significant at	the 1 percent level.		

Figure 6 - relationship between use and resistance, guadratic specification

Significant at the 5 percent level.

*Significant at the 10 percent level.

Here, while the regression of resistance against animal use was not significant, the relationship between human use (in both sectors) and resistance had a positive coefficient on the linear term and a negative coefficient on the quadratic term, suggesting that resistance increases with use but that as use becomes higher the effect on resistance diminishes.

In order to investigate threshold effects, we first graphed use against resistance in each of the sectors (Appendix IV), and saw that the relationship appeared to be more distinctly positive up to a level of resistance of ~0.55. We thus ran truncated regressions for resistance values below this cutoff, also trying cutoffs of 0.50 and 0.60. Because of the low number of data points, we were able to do so for ABU in primary and secondary care, but not in poultry.

I	og Rate of Resistance of O	Campylobacter Samples Tested
	Resistance >= 0.55	Whole Sample
	(1)	(2)
Log Antibiotic Use in Primary Care (Millions of DDDs)	1.528***	1.165***
	(0.150)	(0.142)
Constant	-26.359***	-20.354***
	(2.063)	(1.924)
V	138	167
R ²	0.432	0.291
Adjusted R ²	0.428	0.287
Residual Std. Error	6.642 (df = 136)	6.998 (df = 165)
F Statistic	103.423^{***} (df = 1; 136)	67.838 ^{***} (df = 1; 165)
Notes:	****Si	gnificant at the 1 percent level
	**Si	gnificant at the 5 percent level
		nificant at the 10 percent level
	Log Rate of Resistance o	f Campylobacter Samples Test
	Resistance >= 0.55	Whole Sample
		(2)
log Antibiotic Use in Secondaray Care (Millions of DDDs) 4.261***	3.265***
Log Antibiotic Use in Secondaray Care (Millions of DDDs Constant	(0.890)	(0.784)
Constant	-66.101***	-51.302***
SEC	(12.520)	(11.025)
V	72	83
R ²	0.247	0.177
Adjusted R ²	0.236	0.166
Residual Std. Error	7.902 (df = 70)	7.909 (df = 81)
7 Statistic	22.936 ^{***} (df = 1; 70)	17.363^{***} (df = 1; 81)
Notes:	***	Significant at the 1 percent leve
		Significant at the 5 percent leve

Figure 7 - relationship between resistance and use in primary care, truncated regression

**Significant at the 5 percent level.

*Significant at the 10 percent level.

For use in both human sectors, the truncated regression had a greater degree of statistical significance and explanatory power, and the coefficients had a greater size. This further supports the idea that the relationship between use and resistance begins to break down at higher levels.

We then interacted use in poultry with use in humans (primary care) (Figure 8)

Rate	of Resistance of Campylobacter Samples Tested	Log Rate of Resistance of Campylobacter Samples 7	Tested Log Number of Resistant Infections
	(1)	(2)	(3)
Antibiotic Use in Primary Care (Millions of DDDs)	0.0005		
	(0.001)		
Antibiotic Use in Poultry (Tonnes)	-0.089***		
	(0.025)		
Interaction Term	0.001***		
	(0.0003)		
Antibiotic Use in Primary Care (Log DDDs)		1.334***	1.156
		(0.439)	(1.047)
Antibiotic Use in Poultry (Log Tonnes)		-2.016	-1.193
		(1.519)	(3.549)
Log Interaction Term		0.089	0.148
		(0.108)	(0.300)
Constant	0.284***	-22.804***	-21.053
	(0.052)	(6.672)	(15.350)
N	30	30	42
R ²	0.501	0.278	0.198
Adjusted R ²	0.443	0.195	0.134
Residual Std. Error	0.168 (df = 26)	3.674 (df = 26)	12.074 (df = 38)
F Statistic	8.698 ^{****} (df = 3; 26)	3.334^{**} (df = 3; 26)	3.120^{**} (df = 3; 38)
Notes:			***Significant at the 1 percent level.
			**Significant at the 5 percent level.

Figure 9 interaction between use in primary agree and poultry

In the linear specification, the interaction term had a positive coefficient, but it was not significant in other specifications, and we did not infer a consistent trend regarding the interaction between use in humans and poultry.

After this, we looked at the effect of how recently an antibiotic had been clinically introduced. We regressed ABR against use in primary care, the number of years since introduction (as of 2019), and an interaction term (Figure 9). See

*Significant at the 10 percent level.

Figure 9 - time since antibiotic introduction

	Log Rate of Resista	nce of Campylobacter	Samples Tested
	Primary Care	Secondary Care	Poultry
	(1)	(2)	(3)
Antibiotic Use in Primary Care (Log DDDs)	18.800***		
	(2.955)		
Antibiotic Use in Secondary Care (Log DDDs)		88.088***	
		(19.071)	
Antibiotic Use in Poultry (Log Tonnes)			-13.426
			(14.697)
Time Since Clinical Introduction of Antibiotic Class (Log Years)	52.074***	280.823***	-4.048
	(6.264)	(55.330)	(9.535)
Interaction Term - Primary Care	-4.379***		
	(0.700)		
Interaction Term - Secondary Care		-20.595***	
		(4.417)	
Interaction Term - Poultry			3.215
		<i>vails</i>	(3.450)
Constant	-226.513***	-1,203.756***	14.440
	(25.597)	(238.891)	(40.466)
Ν	167	83	30
R ²	0.524	0.536	0.078
Adjusted R ²	0.515	0.519	-0.028
Residual Std. Error	5.773 (df = 163)	6.010 (df = 79)	4.152 (df = 26)
R ² Adjusted R ² Residual Std. Error F Statistic Notes:	59.711^{***} (df = 3; 163)) 30.441 ^{***} (df = 3; 79	0.732 (df = 3; 26)
Notes: 500		***Significant at	the 1 percent level.
-			the 5 percent level.
			he 10 percent level.
		-	-

For poultry ABU, we did not find evidence that time-since-introduction was related to the rate of ABR. For use in humans, both in primary and secondary care, we found a positive relationship between use and resistance, and that antibiotics which had been introduced longer ago had a higher rate of resistance. In both cases, the interaction term had a negative coefficient, suggesting that the relationship between use and resistance was more pronounced for more recently introduced antibiotics, as expected.

Finally, we regressed resistance against use combined with the amount of poultry produced in each quarter, with an interaction term. However, these specifications did not produce significant results (Appendix V).

Discussion

Epidemiological implications

Our results suggest that the level of resistance in human Campylobacter infections is linked to ABU in humans, with more fragmentary evidence suggesting a link to ABU in poultry. Resistance was more elastic with respect to use in secondary care than to that in primary care. However, use of antibiotics explained only a relatively small portion of the variation in resistance. Lagged use was significantly related to resistance, but we did not find convincing evidence that it had an independent effect.

For many antibiotic classes, resistance did not fall over the study period despite significant falls in antibiotic use (especially in poultry). Combined with the low explanatory power of ABU as a determinant of resistance in our specifications, this means that transmission factors, rather than antibiotic use, could be the key determinant of resistance levels. These could include farm biosecurity, infection prevention and control in human health, travel, and socioeconomic factors, among others.

Alternatively (or additionally), this could suggest that Campylobacter pathogens are reaching a threshold level of resistance to some antibiotics, beyond which resistant strains become endemic and the short-to-medium-term relationship between use and resistance begins to break down. We found some evidence for this in human health. In the quadratic specifications here, the linear term had a positive coefficient and the squared term had a negative coefficient, suggesting that the positive relationship between use and resistance becomes weaker at higher levels of use. We also found that the relationship was stronger when fewer than 55% of tested isolates were resistant, and that the relationship between use and resistance was strongest for more recently introduced antibiotics. All of this suggests that, at least for use in human health, there is a positive relationship between use and resistance, but that this relationship breaks down over time as resistance builds up. It is unclear whether or not such a threshold exists for use in poultry, given the very low data ISCLIC availability.

To our knowledge, this is the first study to use ecological regression to investigate explicitly the possibility of a resistance threshold and endemicity of resistant strains. Further such investigations in different settings in different microbes, with more data on additional variables (such as levels of infection, prevention and control) would allow for further exploration of these phenomena.

Implications for policy and practice

The fact that use itself explained only a small part of change in resistance calls into question the notion that curbing ABU is sufficient to bring ABR down to sustainable levels. This underscores the importance of policies targeting transmission factors, as well as alternative and complementary therapies such as vaccination and bacteriophages.

Combined with the evidence of a resistance threshold, this suggests that reducing resistance once it has already become prevalent may be challenging or may require more drastic reductions in use than we have seen so far. Doing this through antibiotic use reduction alone may not be feasible due to the human health consequences of further reductions, and given that antibiotic use in poultry is already as low as it can ethically be without endangering animal welfare, according to our consultations with industry stakeholders. This highlights the time-sensitive nature of ABR policy and the need to target resistance early on. Within the context of the UK, these results can help to understand why the resistance levels of Campylobacter infections have persisted despite significant advances in antibiotic stewardship in both poultry and human health.

This does not mean that curbing antibiotic use is not worthwhile. Doing so can prevent the emergence of new resistant strains, which may be just as important as reducing the prevalence of existing strains(17,18). It can also avoid future worsening of resistance

prevalence across drug classes. Finally, we cannot rule out that reducing use may engender significant falls in resistance over much longer time periods. Careful attention should therefore be paid to protecting new classes of antibiotic, which would require different interventions from the ones discussed here.

It is also worth noting that, while here we used the prevalence of resistance as an outcome, in reality we want to minimise the occurrence of resistant infections outright. Thus, targeting transmission and biosecurity as early on in the poultry production process as possible is generally preferable(19).

Links to the broader literature

While ecological regression analysis is arguably an underexploited resource for investigating the determinants of ABR(3), a number of recent studies have used it with interesting and promising results. Rahman and Hollis(14) found that, for European countries across a number of drug-pathogen combinations, ABU (in humans and animals) did explain human ABR prevalence, but that the relationship was consistently inelastic, unlike in our own findings where the relationship was generally somewhat elastic. That our results were more elastic than theirs could reflect the need to include additional covariates which may co-cause both use and resistance, or alternatively could simply mean that resistance in *Campylobacter* responds elastically to changes in ABU relative to resistance in most bacterial pathogens. Similar to our results, Adda (2020)(15) found that the relationship between use and resistance was stronger for more recently introduced antibiotics in the United States.

Allel *et al.*(20), using Beta regression across a range of countries, found that human ABU was associated with human ABR and that animal ABU was also associated with human ABR for some drug-pathogen combinations. This echoes our findings of a strong link between human ABR and human ABU, and a less consistent link between human ABR and animal ABU, although in our case this may have simply been due to the relative data scarcity on animal ABU. They also found a link between socioeconomic factors (such as governance) and the prevalence of ABR in humans across a range of drug-pathogen combinations. As in our study, they emphasise that reducing ABU alone will likely not be sufficient to curb ABR, and that improving transmission factors and material living standards must be centred. As in our study also, they identify shortfalls in surveillance on the animal side as a limitation to future research and policy.

The need to ground the relationship between use and resistance within the socioeconomic context is a takeaway both of our work and of the broader literature. Collingon *et al.*(21) support the role of socioeconomic factors in influencing ABR. Across countries, they found univariate association between an index of resistance and a range of socioeconomic factors. Infrastructure and governance remained significant in the multivariate model, and crucially ABU did not. Looking at fluoroquinolone resistant *P. aeruginosa* across European countries, Zhang, Cui and Zhang(22) find that animal use was actually slightly *negatively* associated with resistance in humans, potentially revealing the general need for regression models which consider causal pathways in detail. While they found resistance to have a roughly unit elastic relationship with human use, it was much more responsive to changes in veterinary and medical staffing than to changes in human use (although this did not hold for all pathogens).

medRxiv preprint doi: https://doi.org/10.1101/2024.01.10.24301092; this version posted January 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

These studies in particular reaffirm our case-study finding that, while human and animal ABU do seem to influence ABR in humans, they are not the main determinant of it, a major takeaway from our analysis. Transmission-related and socioeconomic factors should be central to this discussion, and not measuring and including them in our specifications may obscure the relationship between use and resistance. This is especially important given that our case study is one where, for a number of reasons, a strong causal relationship between antibiotic use and resistance would be relatively easy to observe. While beyond the scope of this paper, future investigations into which socioeconomic factors are most relevant to transmission of resistance in Campylobacter, combined with more detailed use and resistance data, could allow us to create models which more closely model causal pathways. This will help to identify socioeconomic policies with the potential to support antibiotic stewardship initiatives.

Strengths and limitations

Resistance in *Campylobacter* is a strong candidate to investigate the relationship between animal ABU and human ABR, for reasons discussed in the methodology section. Reducing ABU in poultry, the main source of human Campylobacter infection, has been a key ABR policy in the UK over the past decade(7,8), and this study has given us the opportunity to interrogate the ecological relationship assumed by that policy. It has also allowed us to investigate the shape of this ecological relationship in detail through the use of various specifications, hoping to give insight into why reductions in ABU have not seemed to engender commensurate reductions in the resistance prevalence of Campylobacter isolates. It is also novel in its use of ecological regression to investigate specifically the possibility of a resistance threshold and endemicity of resistant strains. While Campylobacter infections are generally self-limiting, reducing the need for hospitalisations and resistance testing, changes to resistance prevalence should still be observable in tested isolates.

However, the study was severely limited by the availability and consistency of data. There was a lack of overlap in years covered between datasets, and poultry ABU data were only available annually. A greater degree of statistical power would have enabled us to use fixed or random effects models, to include more covariates, and to get better insight into the role of ABU in poultry. The lack of standardisation of antibiotic designations across datasets also meant that we were obliged to aggregate antibiotics into broad classes, which may have obscured trends.

It should also be kept in mind that the *Campylobacter* infections which are tested for resistance may not be representative of resistance trends in the general population. Future research could investigate the extent to which prevalence of resistance in those most vulnerable to severe Campylobacter infections differs significantly from in the general population.

Methodologically, ecological regression is a powerful tool but has weaknesses. Because it models a purely statistical relationship, it does not allow us to explain underlying biological processes mechanistically. It also makes it difficult to investigate non-use factors which cannot easily be captured in available national data. Especially because we used pooled OLS rather than fixed or random effects, we were not able to investigate differential relationships between use and resistance across antibiotic classes. Due to the limited

timeframe for which we had data, we could not explore the idea that reducing use causes resistance to fall over the long term. Finally, as we looked at the relationship between use and resistance for specific drug classes, we were not able to observe the effect of use on the emergence of new resistant strains.

Future research

Researchers and policymakers will benefit from better centralisation and harmonisation of antibiotic use and resistance data in the UK, across sectors, which should be made publicly available and downloadable in a ready-to-analyse format.

Future research should continue to perform ecological regression analysis across different drugs, pathogens and countries, interrogating existing findings and adding to the growing knowledge base of studies doing so, making sure to include human and animal ABU together. The idea of a resistance threshold should also be explored in new contexts and for other drug-pathogen combinations to guide future policy to contain other resistant strains.

Given the low explanatory power of ABU here, we should investigate in greater detail the role of transmission-related factors which may contribute to the prevalence of ABR. This could include the provision of national data on biosecurity and WASH in farms, environmental contamination by antibiotics and heavy metals, and hospital hygiene measures, in addition to existing data on socioeconomic factors such as crowding in see manus housing.

Conclusion

Our regression results suggest that the rate of antibiotic resistance in human Campylobacter infections in the UK was positively linked with use of antibiotics in humans, with some evidence that it was also linked to antibiotic use in poultry. However, antibiotic use explained a relatively small portion of the changes in resistance and did not appear to be its main determinant. For antibiotic use in human health, we found evidence that the relationship between (antibiotic) use and resistance weakens over time as resistance builds up.

Our results support the idea of a resistance threshold, beyond which resistant strains become endemic and reductions in use become less effective. Antibiotic stewardship remains important, and future policy and research should continue to focus on transmission factors, safeguarding new antibiotics, and alternative and complementary therapies such as vaccination and bacteriophages.

Works cited

- 1. World Bank Group, Pulling Together to Beat Superbugs, International Bank for Reconstruction and Development / World Bank; 2019.
- 2. OECD. Stemming the Superbug Tide: Just A Few Dollars More [Internet]. OECD; 2018 [cited 2022 Mar 9]. (OECD Health Policy Studies). Available from: https://www.oecdilibrary.org/social-issues-migration-health/stemming-the-superbug-tide 9789264307599en
- 3. Emes E, Naylor N, Waage J, Knight G. Quantifying the Relationship between Antibiotic Use in Food-Producing Animals and Antibiotic Resistance in Humans. Antibiotics. 2022 Jan;11(1):66.
- 4. European Centre for Disease Prevention and Control [Internet]. [cited 2022 Aug 11]. Campylobacteriosis. Available from: https://www.ecdc.europa.eu/en/campylobacteriosis
- 5. Nichols GL, Richardson JF, Sheppard SK, Lane C, Sarran C. Campylobacter epidemiology: a descriptive study reviewing 1 million cases in England and Wales between 1989 and 2011. BMJ Open. 2012 Jan 1;2(4):e001179.
- 6. Health [Internet]. 2018 [cited 2022 Aug 11]. NICE Antimicrobial Prescribing Guidelines | Department of Health. Available from: https://www.health-ni.gov.uk/articles/niceantimicrobial-prescribing-guidelines
- 7. Maxwell K. 'Working together works'. Stewardship delivers again on antibiotic reductions [Internet]. The British Poultry Council. 2022 [cited 2023 Jul 17]. Available from: https://britishpoultry.org.uk/working-together-works-stewardship-delivers-again-onantibiotic-reductions/
- 8. GOV.UK [Internet]. [cited 2023 Jul 17]. Veterinary Antimicrobial Resistance and Sales Surveillance 2021. Available from: https://www.gov.uk/government/publications/veterinary-antimicrobial-resistance-andsales-surveillance-2021
- 9. Food Standards Agency [Internet], [cited 2023 Jun 27], Report into the sources of human Campylobacter infection published. Available from: https://www.food.gov.uk/newsalerts/news/report-into-the-sources-of-human-campylobacter-infection-published-0
- 10. Yang Y, Feye KM, Shi Z, Pavlidis HO, Kogut M, J. Ashworth A, et al. A Historical Review on Antibiotic Resistance of Foodborne Campylobacter. Front Microbiol. 2019 Jul 26;10:1509.
- LSHTM [Internet], [cited 2023 Mar 3], SEFASI, Available from: 11. https://www.lshtm.ac.uk/research/centres-projects-groups/sefasi
- 12. R Core Team, R: A language and environment for statistical computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; Available from: https://www.Rproject.org/
- 13. Lang TA, Altman DG. Basic statistical reporting for articles published in biomedical journals: the 'Statistical Analyses and Methods in the Published Literature' or the SAMPL Guidelines. Int J Nurs Stud. 2015 Jan:52(1):5-9.
- 14. Rahman S, Hollis A. The effect of antibiotic usage on resistance in humans and foodproducing animals: a longitudinal, One Health analysis using European data. Front Public Health [Internet]. 2023 [cited 2023 Jun 30];11. Available from: https://www.frontiersin.org/articles/10.3389/fpubh.2023.1170426
- Adda J. Preventing the Spread of Antibiotic Resistance. AEA Pap Proc. 2020 15. May:110:255-9.
- 16. GOV.UK [Internet]. [cited 2023 Jan 6]. Latest poultry and poultry meat statistics. Available from: https://www.gov.uk/government/statistics/poultry-and-poultry-meatstatistics
- Smith D, Harris A, Johnson J, Silbergeld E, Morris J. Animal Antibiotic Use Has an 17. Early but Important Impact on the Emergence of Antibiotic Resistance in Human Commensal Bacteria. Proc Natl Acad Sci U S A. 2002;99(9):6434-9.
- 18. Smith D, Dushoff J, Morris J. Agricultural Antibiotics and Human Health: Does Antibiotic Use in Agriculture Have a Greater Impact than Hospital Use? PLoS Med.

2005;2(8):232.

- 19. Hazards (BIOHAZ) EP on B. Scientific Opinion on Campylobacter in broiler meat production: control options and performance objectives and/or targets at different stages of the food chain. EFSA J. 2011;9(4):2105.
- Allel K, Day L, Hamilton A, Lin L, Furuya-Kanamori L, Moore CE, et al. Global 20. antimicrobial-resistance drivers: an ecological country-level study at the human-animal interface. Lancet Planet Health. 2023 Apr;7(4):e291-303.
- Collignon P, Beggs J, Walsh T, Gandra S, Laxminarayan R. Anthropological and 21. Socioeconomic Factors Contributing to Global Antimicrobial Resistance: A Univariate and Multivariable Analysis. Lancet Planet Health. 2018;2(9).
- Zhang D, Cui Y, Zhang X. Estimating Factors Related to Fluoroguinolone Resistance 22. Based on One Health Perspective: Static and Dynamic Panel Data Analyses from Europe. Front Pharmacol. 2019;3(10).

see manuscript Dr

OI for details


Appendix

Арре							
Append	dix I - harmonising an	ntibiotic classes across	datasets				
Classes listed in poultry health dataset	Unified class	Classes listed in primary care dataset	Unified class	Classes listed in secondary care dataset	Unified class	Classes listed in human infections dataset	Unified class
Aminoglycosides	Aminoglycosides	Aminoglycosides	Aminoglycosides	Aminoglycosides	Aminoglycosides	Amoxicillins	Penicillins
Amoxicillins	Penicillins	Amphenicols	Amphenicols	Amphenicols	Amphenicols	Ampicillins / amoxicillins	Penicillins
Products under the cascade	N/A	Anti-clostridioides difficile agents	N/A	DOI for us		Azithromycins	Macrolides, lincosamides and streptogramins
Doxycyclines	Tetracyclines	BL resistant penicillins	Penicillins	BL resistant penicillins	Penicillins	Ciprofloxacins	Quinolones / fluoroquinolones
Fluoroquinolones	Quinolones / fluoroquinolones	BL sensitive penicillins	Penicillins	BL sensitive penicillins	Penicillins	Clarithromycins	Macrolides, lincosamides and streptogramins
Lincomycins	Macrolides, lincosamides and streptogramins	Carbapenems	Carbapenems	Carbapenems	Carbapenems	Ceftriaxones	Third gen. cephalosporins
Macrolides	Macrolides, lincosamides and streptogramins	Combinations of penicillins, incl. beta- lactamase inhibitors	Penicillins	Combinations of penicillins, incl. beta- lactamase inhibitors	Penicillins	Cefotaximes	Third gen. cephalosporins
Penicillins	Penicillins	First gen. cephalosporins	First gen. cephalosporins	First gen. cephalosporins	First gen. cephalosporins	Ceftazidimes	Third gen. cephalosporins
Pleuromutilins	Pleuromutilins	Fluoroquinolones	Quinolones / fluoroquinolones	Fluoroquinolones	Quinolones / fluoroquinolones	Ertapenems	Carbapenems
				Fourth gen. cephalosporins	Fourth gen. cephalosporins		


		-					
Polymyxins	Polypeptides	Glycopeptide antibacterials	Glycopeptides	Glycopeptide antibacterials	Glycopeptides	Erythromycins	Macrolides, lincosamides and streptogramins
Potentiated sulphonamides	Sulfonamides and trimethoprims	Imidazole derivatives	Azoles	Imidazole derivatives	Azoles	Gentamicins	Aminoglycosides
Tetracyclines	Tetracyclines	Intestinal antiinfectives	N/A	Intestinal antiinfectives	N/A	Imipenems	Carbapenems
		Macrolides, lincosamides and streptogramins	Macrolides, lincosamides and streptogramins	Macrolides, lincosamides and streptogramins	Macrolides, lincosamides and streptogramins	Levofloxacins	Quinolones / fluoroquinolones
		Monobactams	Monobactams	Monobactams	Monobactams	Meropenems	Carbapenems
		Nitrofuran derivatives	Nitrofurans	Nitrofuran derivatives	Nitrofurans	Tetracyclines	Tetracyclines
		Other antibacterials	N/A nusur	Other antibacterials	N/A		
		See	Mo	Other cephalosporins and penems	N/A		
		Penicillins with extended spectrum	Penicillins	Penicillins with extended spectrum	Penicillins		
		Polymyxins	Polypeptides	Polymyxins	Polypeptides		
		Second gen. cephalosporins	Second gen. cephalosporins	Second gen. cephalosporins	Second gen. cephalosporins		
		Steroid antibacterials	Steroid antibacterials	Steroid antibacterials	Steroid antibacterials		
		Sulfonamides and trimethoprims	Sulfonamides and trimethoprims	Sulfonamides and trimethoprims	Sulfonamides and trimethoprims		
		Tetracyclines	Tetracyclines	Tetracyclines	Tetracyclines		
		Third gen. cephalosporins	Third gen. cephalosporins	Third gen. cephalosporins	Third gen. cephalosporins		


Appendix II - data completeness chart					
Antibiotic Class	Use in primary healthcare (2013 - 2021)	Use in secondary healthcare (2017 - 2022)	Use in poultry (2011 - 2021)	Rate of resistance in human infections (2014 - 2019)	Data present for all variables
Aminoglycosides	Y	Y	Y	Y	Y
Amphenicols	Y	Y	Ν	Ν	Ν
Anti-Clostridioides difficile agents	Ν	Ν	Ν	N	Ν
Azoles	Y	Y	Ν	N	Ν
Carbapenems	Y	Y	Ν	Y	Ν
Coamoxiclav (amoxicillin with clavulanic acid)	Ν	Ν	N	Ν	Ν
Cephalosporins (1st gen)	Y	Y	N	N	Ν
Cephalosporins (2nd gen)	γ	Υ	N detai	N	Ν
Cephalosporins (3rd gen)	Y	P D	NTOT	Y	Ν
Cephalosporins (4th gen)	N	Y cript	Ν	Ν	Ν
Cephalosporins (5th gen)	N mani	Nz	Ν	Ν	Ν
Glycopeptides	zee III	Y	Ν	Ν	Ν
Intestinal antiinfectives	N	Ν	Ν	Ν	Ν
Macrolides, lincosamides, and streptogramins	Y	Υ	Y	Y	Y
Monobactams	Y	Y	Ν	Ν	Ν
Nitrofurans	Y	Y	Ν	Ν	Ν
Other cephalosporins and penems	Ν	Ν	Ν	Ν	Ν
Penicillins	Y	Y	Y	Y	Y
Pleuromutilins	Ν	Ν	Y	Ν	Ν
Polypeptides	Y	Y	Y	Ν	Ν
Quinolones and fluoroquinolones	Y	Y	Y	Y	Y
Steroid antibacterials	Y	Y	Ν	Ν	Ν
Sulfonamides and trimethoprims	Y	Y	Y	Ν	Ν
Tetracyclines	Y	Y	Y	Y	Y

Appendix II - data completeness chart



Appendix III - data cleaning procedure flowchart





Log Rate of Resistance of Campylobacter Samples Tested (2)(3)(1)7.019 Antibiotic Use in Primary Care (Log DDDs) (13.755) Antibiotic Use in Secondary Care (Log DDDs 159.049 (169.829)16.826 Antibiotic Use in Poultry (Log Tonnes) (13.652 10.013 Poultry Production (Log Tonnes) 371.031 6.013 (30.689) (387.504) (4.769) -0.957 Interaction with Primary Care Use (2.248)-25.289 Interaction with Secondary Care Use (27.567) det Interaction with Poultry Use -2.225 -81.600 1001 (1.812)-81:509 -2,336.850 -46.852 Constant (2,387.185)(35.827) N 30 83 \mathbb{R}^2 0.188 0.083 -0.023 Adjusted R² 0.157 7.035 (df = 163) 7.952 (df = 79)Residual Std. Error 1.207 (df = 26)F Statistic 22.466^{***} (df = 3; 163) 6.104^{***} (df = 3; 79) 0.780 (df = 3; 26)

Appendix V - specifications controlling for poultry production

Notes:

***Significant at the 1 percent level.

**Significant at the 5 percent level.

*Significant at the 10 percent level.